Glenmark Pharmaceuticals rises as its arm acquires, launches Acetylcysteine Injection
Glenmark Pharmaceuticals is currently trading at Rs. 1283.55, up by 4.80 points or 0.38% from its previous closing of Rs. 1278.75 on the BSE.
The scrip opened at Rs. 1275.10 and has touched a high and low of Rs. 1290.85 and Rs. 1275.10 respectively. So far 2893 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1830.05 on 15-Oct-2024 and a 52 week low of Rs. 883.50 on 14-Mar-2024.
Last one week high and low of the scrip stood at Rs. 1352.70 and Rs. 1274.70 respectively. The current market cap of the company is Rs. 36207.56 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 37.40% and 15.96% respectively.
Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc, USA has acquired and launched Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials. Glenmark’s Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials can be expected to have the same therapeutic effect as the listed drug product upon which the Agency relied as the basis of safety and effectiveness, Acetadote Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials of Cumberland Pharmaceuticals Inc. Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA Inc.
According to IQVIATM sales data for the 12-month period ending January 2025, the Acetadote Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials market achieved annual sales of approximately $15.2 million.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
